Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5AP | P20292 | 6/20 | 0.56 |
| ▸ | FEN1 | P39748 | 6/20 | 0.56 |
| ▸ | CA12 | O43570 | 1/20 | 0.51 |
| ▸ | CA2 | P00918 | 1/20 | 0.51 |
| ▸ | CA9 | Q16790 | 1/20 | 0.51 |
| ▸ | PTGES2 | Q9H7Z7 | 3/20 | 0.50 |
| ▸ | F10 | P00742 | 2/20 | 0.50 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.45 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.45 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.45 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.43 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.43 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.43 |
| ▸ | TDO2 | P48775 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8661936 | 0.93 | ALOX5AP (0.50) | ALOX5APFEN1CA12CA2CA9 | |
| SCHEMBL8657938 | 0.89 | ALOX5AP (0.50) | ALOX5APFEN1CA12CA2CA9 | |
| Methyl Alcohol SCHEMBL8659448 | 0.89 | ALOX5AP (0.49) | ALOX5APFEN1CA12CA2CA9 | |
| SCHEMBL8659722 | 0.85 | CA2 (0.45) | ALOX5APFEN1CA12CA2CA9 | |
| SCHEMBL778996 | 0.83 | PTPN1 (0.46) | ALOX5APFEN1PTGES2F10MAOB | |
| SCHEMBL3836209 | 0.83 | ALOX5AP (0.48) | ALOX5APFEN1PTGS1PTGS2MAOB | |
| SCHEMBL8658034 | 0.82 | PTGS2 (0.46) | ALOX5APFEN1CA12CA2CA9 | |
| SCHEMBL8629486 | 0.82 | ALOX5AP (0.44) | ALOX5APFEN1CA12CA2CA9 | |
| SCHEMBL6613230 | 0.81 | CA1 (0.54) | ALOX5APFEN1CA12CA2CA9 | |
| SCHEMBL2308295 | 0.81 | CA2 (0.56) | CA12CA2CA9PTGES2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2382191-A1 | NOVEL BENZENESULFONAMIDES AS CALCIUM CHANNEL BLOCKERS | Abbott Laboratories, Inc. (US) | 2011-11-02 | — | — | EP | claimed |
| US-9745328-B2 | Flap modulators | JANSSEN PHARMACEUTICA NV (BE) | 2017-08-29 | — | — | US | disclosed |
| US-20150376212-A1 | FLAP MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2015-12-31 | — | — | US | disclosed |
| EP-2382191-A1 | NOVEL BENZENESULFONAMIDES AS CALCIUM CHANNEL BLOCKERS | Abbott Laboratories, Inc. (US) | 2011-11-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150376212-A1 | FLAP MODULATORS | FEN1, PGF, TBXA2R | ALOX5AP 95/4885FEN1 1/4885CA12 3617/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.